Trial Profile
A Phase 2 Multicenter Trial of Pediatric Autologous Bone Marrow Mononuclear Cells (BMMNCs) for Severe Traumatic Brain Injury (TBI)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs CEVA 101 (Primary)
- Indications Traumatic brain injuries
- Focus Therapeutic Use
- 12 Nov 2020 Status changed from active, no longer recruiting to completed.
- 12 May 2020 Planned End Date changed from 1 Feb 2020 to 1 Aug 2020.
- 12 May 2020 Planned primary completion date changed from 1 Feb 2020 to 1 Jul 2020.